Factors influencing growth effects of inhaled corticosteroids in children
A 9-year, 10-month-old boy treated with inhaled corticosteroids (ICSs) for asthma returned to the endocrine clinic for follow-up of linear growth. He began taking Advair Diskus (100/50; GlaxoSmithKline, Research Triangle Park, NC), 1 inhalation twice daily, when he was 4 years old. During treatment with Advair Diskus, he grew steadily along his previous height trajectory at between the 75th and 90th percentiles (Fig 1). Around 6 years of age, treatment was changed to Advair hydrofluoroalkane (HFA; 45/21), 2 inhalations twice daily. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - December 1, 2015 Category: Allergy & Immunology Authors: Peter M. Wolfgram, David B. Allen Tags: Maintenance of Certification clinical management series Source Type: research
Response to Letter to the Editor: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
On behalf of my co-authors, I would like to thank Dr Banerji and Dr Patalano for their interest in our recently published article demonstrating the benefits of once-daily umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI) versus twice-daily fluticasone propionate/salmeterol 250/50 mcg (FP/SAL) in patients with moderate-to-severe COPD. Dr Banerji and Dr Patalano quite rightly highlight the similarities of our findings and those of the ILLUMINATE and LANTERN studies [1,2], which further support the benefits of combined long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) treatments in COPD. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - November 27, 2015 Category: Respiratory Medicine Authors: James F. Donohue Source Type: research
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
On behalf of my co-authors, I would like to thank Dr Banerji and Dr Patalano for their interest in our recently published article demonstrating the benefits of once-daily umeclidinium/vilanterol 62.5/25 mcg (UMEC/VI) versus twice-daily fluticasone propionate/salmeterol 250/50 mcg (FP/SAL) in patients with moderate-to-severe COPD. Dr Banerji and Dr Patalano quite rightly highlight the similarities of our findings and those of the ILLUMINATE and LANTERN studies [1, 2], which further support the benefits of combined long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) treatments in COPD. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - November 27, 2015 Category: Respiratory Medicine Authors: James F. Donohue Source Type: research
Bioassay of salmeterol in children using methacholine challenge with impulse oscillometry
ConclusionsMC with IOS endpoint will be a useful method for determining bioequivalence of a generic inhaler in children. Seventy‐two subjects will be required to achieve 80% power to assess bioequivalence of SM. Pediatr Pulmonol. © 2015 Wiley Periodicals, Inc. (Source: Pediatric Pulmonology)
Source: Pediatric Pulmonology - November 17, 2015 Category: Respiratory Medicine Authors: Pritish Mondal, Sandra Baumstein, Sreekala Prabhakaran, Mutasim Abu‐Hasan, Yaohui Zeng, Sachinkumar Singh, Kai Wang, Richard C. Ahrens, Leslie Hendeles Tags: Original Article: Asthma Source Type: research
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis
Conclusion:
Results of an NMA of COPD treatments suggest that SFC and indacaterol may reduce mortality. Further research is warranted to strengthen this conclusion. (Source: BMC Pulmonary Medicine)
Source: BMC Pulmonary Medicine - November 11, 2015 Category: Respiratory Medicine Authors: David A ScottBethan WoodsJuliette C ThompsonJames F ClarkNeil HawkinsMike ChambersBartolome CelliPeter Calverley Source Type: research
Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD
Conclusion: Superiority in peak FEV1 and non-inferiority in TDI were demonstrated for aclidinium/formoterol FDC vs SAL/FLU in pts with stable COPD. Improvements in quality of life and exacerbations were similar in both groups. More pts preferred Genuair to Accuhaler. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Vogelmeier, C., Paggiaro, P. L., Dorca, J., Sliwinski, P., Mallet, M., Kirsten, A.-M., Seoane, B., Segarra, R. M., Leselbaum, A., Gil, E. G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Conclusions: Aclidinium/formoterol and salmeterol/fluticasone FDCs were well tolerated in patients with COPD. Incidence of CV AEs was low. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Beier, J., Vogelmeier, C., Mroz, R., Pascual, S., Segarra, R. M., Lei, A., De Miquel, G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Triple therapy of umeclidinium and inhaled corticosteroid/long-acting {beta}2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients
Conclusion: In GOLD D patients, adding UMEC 62.5 to ICS/LABA improved lung function and reduced exacerbation risk.Funded by GSK NCT01957163, 200109; NCT02119286, 200110; NCT01772134, AC4116135; NCT01772147, AC4116136. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Kerwin, E., Siler, T., Tombs, L., Sousa, A. R., Singletary, K., Church, A. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients
Robust biomarkers for COPD may help direct patient-specific therapy, e.g. sputum eosinophilia in COPD patients predicts clinical response to ICS (Brightling C.E. et al. Thorax 2005:60:193-8). Peripheral blood eosinophil count has also been proposed as a biomarker to direct corticosteroid therapy during COPD exacerbations. We wished to quantify the extent to which ICS affected peripheral blood eosinophil count and conducted post-hoc analysis on two randomised, double-blind, placebo-controlled intervention studies in stable, steroid-naïve COPD subjects. RES106087 (NCT00379730) was a 6 wk study comparing placebo (n=44...
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Kreindler, J., Locantore, N., Watkins, M., Lettis, S., Tal-Singer, R. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
Tissue distribution of inhalation drugs in rat lung slices
Conclusions: The uptake of inhalation drugs depends on physicochemical properties, such as ion class, pKa, and lipophilicity. The resulting Vu,lung data can be used to gain a greater understanding of lung exposure. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Bäckström, E., Lundqvist, A., Boger, E., Svanberg, P., Ewing, P., Hammarlund-Udenaes, M., Friden, M. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Conclusions: This study suggests that using LABA/ICS, F+S in this study, in moderate/severe COPD may provide sub-optimal lung-function improvements compared to T+O. Funding: Boehringer Ingelheim. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Beeh, K.-M., Derom, E., Echave-Sustaeta, J., Groenke, L., Hamilton, A., Zhai, D., Bjermer, L. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research
LATE-BREAKING ABSTRACT: Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD patients
Conclusions: In moderate COPD patients ICS-treatment is associated with a significant increase in airway total bacterial load, not related to clinical outcomes, when eosinophils are persistently absent in sputum samplesThe study was supported by unrestricted grant from GlaxoSmithKline. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Contoli, M., Pauletti, A., Casolari, P., Gnesini, G., Magnoni, M. S., Curradi, G., Forini, G., Marku, B., Papi, A. Tags: 10.1 Respiratory Infections Source Type: research
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level
Conclusions: OS negatively correlate with SP-D in pts with COPD. 2. Treatment with ICS+LABA combination in COPD pts with high plasma SP-D leads to the great improving in OS and significant plasma SP-D declining.High plasma SP-D level could be considered as an additional criterion for ICS+LABA prescription in COPD pts, especially in those one who suffer from hypoxia. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Pertseva, T., Gashynova, K., Kravchenko, N. Tags: 1.12 Clinical Problems - COPD Source Type: research
Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide
Conclusion: These results suggested that triple therapy using SFC250 and TIO improves lung functions compared with the individual treatments and was tolerated in Japanese COPD patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Takaku, T., Saito, T., Takeda, A., Hashimoto, K., Kobayashi, A., Hayamizu, T., Hagan, G. Tags: 1.12 Clinical Problems - COPD Source Type: research
Economic Evaluation Of Fluticasone Propionate/Formoterol Fumarate (Flutiform®) Vs Fluticasone/Salmeterol And Budesonide/Formoterol In Spain
To estimate the Cost-Effectiveness of Fluticasone propionate/Formoterol fumarate (FPF) versus Fluticasone/Salmeterol (FS) and Budesonide/Formoterol (BF) in the treatment of adult patients with moderate to severe asthma from the perspective of the Society in Spain. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: E Martínez-Moragón, J Delgado, P Ojeda, L Pérez del Llano, C Antón, C Martín, JM Collar Source Type: research
